

# Prof. EMİNE ŞALVA

## Personal Information

**Email:** emine.salva@inonu.edu.tr

**Web:** <https://avesis.inonu.edu.tr/emine.salva>

## International Researcher IDs

ORCID: 0000-0002-1159-5850

Publons / Web Of Science ResearcherID: CAH-3062-2022

Yoksis Researcher ID: 111228

## Education Information

Postgraduate, Inonu University, Sağlık Bilimleri Enstitüsü, Tıbbi Biyoloji Ve Genetik (YI) (Tezli), Turkey 2015 - 2019

Doctorate, Marmara University, Institute Of Health Sciences, Farmasötik Biyoteknoloji, Turkey 2003 - 2009

Postgraduate, Inonu University, Sağlık Bilimleri Enstitüsü, Biyokimya (Tıp Programı), Turkey 2001 - 2003

Undergraduate, Hacettepe University, Fen Fakültesi, Biyoloji Bölümü, Turkey 1993 - 1997

## Foreign Languages

English, B2 Upper Intermediate

## Dissertations

Doctorate, siRNA için uygun taşıyıcı sistem geliştirilmesi; in vitro ve in vivo çalışmalar, Marmara University, Sağlık Bilimleri Enstitüsü, Farmosotik Biyoteknoloji (Bütünleşik Dr), 2009

Postgraduate, Tip I ve Tip II Diabetes Mellituslu Hastalarda Serumda Ferritin ve Transferrin, İdrarda beta-2-mikroglobulin Düzeylerinin İncelenmesi, Inonu University, Sağlık Bilimleri Enstitüsü, Tıbbi Biyokimya (YI), 2003

## Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Biotechnology

## Academic Titles / Tasks

Professor, Inonu University, Eczacılık Fakültesi, Eczacılık Teknolojisi, 2023 - Continues

Associate Professor, Inonu University, Eczacılık Fakültesi, Eczacılık Teknolojisi, 2019 - 2023

Assistant Professor, Inonu University, Eczacılık Fakültesi, Eczacılık Teknolojisi, 2012 - 2018

Lecturer, Marmara University, Vocational School Of Health Services, Patoloji Laboratuvar Bölümü, 2003 - 2012

Research Assistant, Marmara University, Vocational School Of Health Services, Patoloji Laboratuvar Bölümü, 2001 - 2003

## Academic and Administrative Experience

Head of Department, Inonu University, Eczacılık Fakültesi, Eczacılık Teknolojisi, 2019 - Continues  
Inonu University, 2012 - Continues  
Inonu University, Eczacılık Fakültesi, 2013 - 2016  
Head of Department, Inonu University, Eczacılık Teknoloji , 2013 - 2016

## Courses

Hücre Kültür Teknolojisi, Undergraduate, 2016 - 2017  
FARMASÖTİK BİYOTEKNOLOJİ, Undergraduate, 2016 - 2017  
SOSYAL SORUMLULUK PROJELERİ, Undergraduate, 2016 - 2017  
Araştırma Projesi I, Undergraduate, 2016 - 2017  
ENDÜSTRİYEL BİYOTEKNOLOJİ, Undergraduate, 2016 - 2017  
SOSYAL SORUMLULUK PROJELERİ, Undergraduate, 2016-2017  
FARMASÖTİK BİYOTEKNOLOJİ, Undergraduate, 2016-2017  
Araştırma Projesi I, Undergraduate, 2016-2017  
ENDÜSTRİYEL BİYOTEKNOLOJİ, Undergraduate, 2016-2017  
Hücre Kültür Teknolojisi, Undergraduate, 2016-2017  
Araştırma Projesi II, Undergraduate, 2015-2016  
FARMASÖTİK BİYOTEKNOLOJİ, Undergraduate, 2015-2016  
TIBBİ BİYOLOJİ, Undergraduate, 2015-2016  
Araştırma Projesi I, Undergraduate, 2015-2016  
GEN VE İLAÇ TAŞIYICI SİSTEMLER, Undergraduate, 2015-2016  
REKOMBİNANT BİYOFARMASÖTİKLER, Undergraduate, 2015-2016  
Sosyal Sorumluluk Projeleri, Undergraduate, 2015-2016  
TIBBİ BİYOLOJİ, Undergraduate, 2014-2015  
Sosyal Sorumluluk Projeleri, Undergraduate, 2014-2015  
Araştırma Projesi I, Undergraduate, 2014-2015  
ENDÜSTRİYEL BİYOTEKNOLOJİ, Undergraduate, 2014-2015  
FARMASÖTİK BİYOTEKNOLOJİ, Undergraduate, 2014-2015  
Araştırma Projesi II, Undergraduate, 2014-2015  
REKOMBİNANT BİYOFARMASÖTİKLER, Undergraduate, 2013-2014  
Tıbbi Biyoloji, Undergraduate, 2013-2014  
ENDÜSTRİYEL BİYOTEKNOLOJİ, Undergraduate, 2013-2014  
Farmasötik Biyoteknoloji, Undergraduate, 2013-2014  
Araştırma Projesi II, Undergraduate, 2013-2014  
Araştırma Projesi I, Undergraduate, 2013-2014  
Gen ve İlaç Taşıyıcı Sistemler, Undergraduate, 2012-2013  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2011-2012  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2011-2012  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2011-2012  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2010-2011  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2010-2011  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2010-2011  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2010-2011  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2010-2011  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2010-2011  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2010-2011  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2010-2011  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2010-2011  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2009-2010

PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2009-2010  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2009-2010  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2009-2010  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2009-2010  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2009-2010  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2009-2010  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2009-2010  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2009-2010  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2008-2009  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2008-2009  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2008-2009  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2008-2009  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2008-2009  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2008-2009  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2008-2009  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2008-2009  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2007-2008  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2007-2008  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2007-2008  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2007-2008  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2007-2008  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2007-2008  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2007-2008  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2007-2008  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2007-2008  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2006-2007  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2006-2007  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2006-2007  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2006-2007  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2006-2007  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2006-2007  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2006-2007  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2005-2006  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2005-2006  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2005-2006  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2005-2006  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2005-2006  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2005-2006  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2005-2006  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2005-2006  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2005-2006  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2004-2005  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2004-2005  
PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2004-2005  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2004-2005  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2004-2005  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2004-2005  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2004-2005  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2004-2005  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2004-2005  
MOLEKÜLER PATOLOJİ TEKNİKLERİ, Associate Degree, 2003-2004

PATOLOJİ LAB. TEK. UYG. II, Associate Degree, 2003-2004  
PATOLOJİ LAB. GÜVENLİK, Associate Degree, 2003-2004  
PATOLOJİDE ÖZEL TEKNİKLER, Associate Degree, 2003-2004  
ÖZEL HİSTOKİMYA TEKNİKLERİ, Associate Degree, 2003-2004  
PATOLOJİ LAB. TEK. UYG. I, Associate Degree, 2003-2004  
PATOLOJİ LAB. TEK. UYG. III, Associate Degree, 2003-2004  
PATOLOJİ LAB. TEK. UYG. IV, Associate Degree, 2003-2004  
GENEL HİSTOTEKNOLOJİ I, Associate Degree, 2003-2004

## Advising Theses

ŞALVA E., Kitozanın Keratinositler Üzerine Etkisinin 3-Boyutlu Deri Hücre Kültürü Modelinde Araştırılması, Postgraduate, H.Merve(Student), Continues  
ŞALVA E., Doku Mühendisliği Uygulamaları İçin Kitozan-Aljinat-Protamin İçeren Destek Yapıların Hazırlanması ve Karakterizasyonu, Postgraduate, A.Sirkeci(Student), 2016  
ŞALVA E., MikroRNA (miR-200c ve miR-141) İÇİN MEME KANSERİ TEDAVİSİNDE KİTOZAN TEMELLİ TAŞIYICI SİSTEMLERİN GELİŞTİRİLMESİ, Postgraduate, K.Kaban(Student), 2015

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **An effective VEGF-siRNA delivery via folic acid decorated and pegylated silica nanoparticles**  
Ultav G., TONBUL H., ŞALVA E.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.76, 2022 (SCI-Expanded)
- II. **EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts**  
KEHRİBAR D. Y., Emmungil H., BAŞAK TÜRKMEN N., ÇİFTÇİ O., ŞALVA E., Ozgen M.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1355-1361, 2022 (SCI-Expanded)
- III. **Investigation of therapeutic effects in the wound healing of chitosan/pGM-CSF complexes**  
ŞALVA E., ALAN S., Karakoyun B., Cakalagaoglu F., ÖZBAŞ S., Akbuga J.  
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.58, 2022 (SCI-Expanded)
- IV. **Synthesis of New 1-Aryl-2-(3,5-dimethylpyrazol-1-yl)ethanone Oxime Ether Derivatives and Investigation of Their Cytotoxic Effects**  
ALAGÖZ M. A., KARAKURT A., Hepokur C., ŞALVA E., Onkol T., Ghoneim M. M., Abdelgawad M. A., Khames A., Kim H., Mathew B.  
PROCESSES, vol.9, no.11, 2021 (SCI-Expanded)
- V. **Evaluation of biological activities of Barbarea integrifolia and isolation of a new glucosinolate derivated compound**  
Badem M., ŞENER S. Ö., KANBOLAT Ş., Korkmaz N., YILDIRMIŞ S., ÖZGEN U., ALİYAZICIOĞLU R., ŞALVA E., Kaban K., KANDEMİR A., et al.  
ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES, vol.76, no.9-10, pp.375-382, 2021 (SCI-Expanded)
- VI. **Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer**  
Kaban K., Hinterleitner C., Zhou Y., ŞALVA E., KANTARCI A. G., Salih H. R., Maerklin M.  
CANCERS, vol.13, no.10, 2021 (SCI-Expanded)
- VII. **p-Trifluoroacetophenone Oxime Ester Derivatives: Synthesis, Antimicrobial and Cytotoxic Evaluation and Molecular Modeling Studies**  
Bozbeý I., SARI S., ŞALVA E., KART D., KARAKURT A.  
LETTERS IN DRUG DESIGN & DISCOVERY, vol.17, no.2, pp.169-183, 2020 (SCI-Expanded)
- VIII. **Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer**

cells

Kaban K, ŞALVA E, Akbuga J.

JOURNAL OF GENE MEDICINE, vol.21, no.9, 2019 (SCI-Expanded)

- IX. **Synthesis and cytotoxicity studies on new pyrazole-containing oxime ester derivatives**  
KARAKURT A, Bozbey I, USLU H, SARI S, ÖZDEMİR Z, ŞALVA E.  
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol.18, no.6, pp.1315-1322, 2019 (SCI-Expanded)
- X. **Synthesis of triazolylmethyl-linked nucleoside analogs via combination of azidofuranoses with propargylated nucleobases and study on their cytotoxicity**  
HALAY E., AY E., ŞALVA E., AY K., KARAYILDIRIM T.  
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol.54, no.2, pp.158-166, 2018 (SCI-Expanded)
- XI. **In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells**  
Kaban K, ŞALVA E, Akbuga J.  
NUCLEIC ACID THERAPEUTICS, vol.27, no.1, pp.45-55, 2017 (SCI-Expanded)
- XII. **Syntheses of 1,2,3-triazole-bridged pyranose sugars with purine and pyrimidine nucleobases and evaluation of their anticancer potential**  
HALAY E., AY E., ŞALVA E., AY K., KARAYILDIRIM T.  
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, vol.36, no.9, pp.598-619, 2017 (SCI-Expanded)
- XIII. **The effects of chitosan/miR-200c nanoplexes on different stages of cancers in breast cancer cell lines**  
Kaban K, ŞALVA E, Akbuga J.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.95, pp.103-110, 2016 (SCI-Expanded)
- XIV. **Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model**  
Elcioglu H. K., Aslan E., Ahmad S., ALAN S., ŞALVA E., Elcioglu O. H., KABASAKAL L.  
MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.420, pp.21-28, 2016 (SCI-Expanded)
- XV. **Comparison of VEGF gene silencing efficiencies of chitosan and protamine complexes containing shRNA**  
Erdem-Cakmak F., ÖZBAŞ S., ŞALVA E., Akbuga J.  
CELL BIOLOGY INTERNATIONAL, vol.38, no.11, pp.1260-1270, 2014 (SCI-Expanded)
- XVI. **Investigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model**  
ŞALVA E., TURAN S. O., Kabasakal L., ALAN S., Ozkan N., EREN F., Akbuga J.  
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.103, no.3, pp.785-795, 2014 (SCI-Expanded)
- XVII. **The Development of Ternary Nanoplexes for Efficient Small Interfering RNA Delivery**  
ŞALVA E., Turan S. O., Akbuga J.  
BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol.36, no.12, pp.1907-1914, 2013 (SCI-Expanded)
- XVIII. **Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo.**  
Salva E., KABASAKAL L., EREN F., ÖZKAN N., CAKALAĞAOĞLU F., AKBUGA J.  
Nucleic acid therapeutics, vol.22, pp.40-8, 2012 (SCI-Expanded)
- XIX. **Honey as a substitute for formalin?**  
ÖZKAN N., Salva E., CAKALAĞAOĞLU F., TÜZÜNER B.  
Biotechnic & histochemistry : official publication of the Biological Stain Commission, vol.87, pp.148-53, 2012 (SCI-Expanded)
- XX. **Increased in vitro Cell Proliferation by Chitosan/pGM-CSF Complexes**  
Salva E., TURAN S., Akbuga J.  
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.73, no.2, pp.131-138, 2011 (SCI-Expanded)
- XXI. **In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines**  
Salva E., Akbuga J.  
PHARMAZIE, vol.65, no.12, pp.896-902, 2010 (SCI-Expanded)

- XXII. **Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma.**  
Salva E., KABASAKAL L., EREN F., CAKALAĞAOĞLU F., ÖZKAN N., AKBUGA J.  
Oligonucleotides, vol.20, pp.183-90, 2010 (SCI-Expanded)
- XXIII. **Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis.**  
KARAKOYUN B., YÜKSEL M., ERCAN F., Salva E., IŞIK I., YEĞEN B.  
Digestive diseases and sciences, vol.55, pp.607-16, 2010 (SCI-Expanded)
- XXIV. **Significance of IL-6 and PAI-1 expression in nucleic-acid based therapy of breast cancer**  
Cakalagaoglu F., Salva E., Ozkan N., KAYA H., KABASAKAL L., Akbuga J.  
VIRCHOWS ARCHIV, vol.455, pp.103, 2009 (SCI-Expanded)
- XXV. **Double immunostaining method. What is the significance?**  
OZKAN N., CAKALAGA OGLU F., Salva E.  
VIRCHOWS ARCHIV, vol.451, no.2, pp.565, 2007 (SCI-Expanded)
- XXVI. **The effects in skin wound healing and cell proliferation of the plasmid DNA encoding GM-CSF and chitosan**  
Salva E., OZKAN N., CAKALAGA OGLU F., KARAKOYUN B., AKBUGA J.  
VIRCHOWS ARCHIV, vol.451, no.2, pp.565, 2007 (SCI-Expanded)
- XXVII. **Effect of FK506 in experimental glomerulonephritis: Light microscopic and ultrastructural study**  
CAKALAPA OGLU F., OZKAN N., Salva E., ARBAK S., USLU B.  
VIRCHOWS ARCHIV, vol.451, no.2, pp.513-514, 2007 (SCI-Expanded)
- XXVIII. **The staining methods of chitosan as a natural biopolymer**  
Salva E., OZKAN N., CAKALAGA OGLU F., KARAKOYUN B., AKBUGA J.  
VIRCHOWS ARCHIV, vol.451, no.2, pp.539-540, 2007 (SCI-Expanded)

## Articles Published in Other Journals

- I. **A New Gene Therapy Approach by Tenascin-C Genome Editing Induces Apoptosis and Cell Cycle Arrest in Triple Negative Breast Cancer Cells**  
Bareke H., Salva E., OZBAS TURAN S.  
Cyprus Journal of Medical Sciences, vol.8, no.1, pp.20-26, 2023 (Peer-Reviewed Journal)
- II. **Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells**  
Canak Ipek T., Avci-Adali M., ATICI C. E., Salva E., OZBAS TURAN S.  
Journal of research in pharmacy (online), vol.27, no.1, pp.86-96, 2023 (Peer-Reviewed Journal)
- III. **Antiproliferative properties and evaluation of antioxidant of different cornelian cherry genotypes and analysis of phenolic and sugar compounds by HPLC**  
UĞUR Y., ŞALVA E., KARAAT F. E., ERDOĞAN S.  
Hacettepe Journal of Biology and Chemistry, vol.51, no.1, pp.57-70, 2023 (Peer-Reviewed Journal)
- IV. **Development of Silica Nanoparticles as a Delivery System for Plasmid-Based Crispr/Cas9**  
ULTAV G., MAÇ K., KIZILBOĞA S., GÜNDOĞDU V., TONBUL H., ŞALVA E.  
Anatolian Journal of Pharmaceutical Sciences, vol.1, no.1, pp.33-39, 2022 (Peer-Reviewed Journal)
- V. **Relationship between guanosine triphosphate pathway and tetrahydrobiopterin in gestational diabetes mellitus**  
Ünüvar S., Melekoğlu R., Şalva E., Acar C., Yaşar Ş.  
Journal of Diabetes & Metabolic Disorders, vol.1, pp.1-6, 2020 (ESCI)
- VI. **INVESTIGATION OF THE EFFECT OF VEGFshRNAs CLONED INTO SILENCING PLASMIDS ON VEGF EXPRESSION IN ENDOTHELIAL CELL**  
Şalva E., Yeşilada E.  
International Multidisciplinary Symposium on Drug Research & Development (DRD 2019), vol.1, no.1, pp.313-316, 2019 (Conference Book)

- VII. **The Effects to GM-CSF Expression and Fibroblast Proliferation of pGM-CSF Containing Chitosan/PVP Hydrogels**  
ŞALVA E., Akbuga J.  
MARMARA PHARMACEUTICAL JOURNAL, vol.21, no.2, pp.228-234, 2017 (ESCI)
- VIII. **In Vitro PDGF-B Gene Silencing Studies and In Vivo Delivery of siRNA to the Rat Kidney Using Chitosan/siRNA Nanoplexes**  
ŞALVA E., Ozbas Turan S., ALAN S., Akbuga J.  
MARMARA PHARMACEUTICAL JOURNAL, vol.20, no.3, pp.263-268, 2016 (ESCI)

## Books & Book Chapters

- I. **Biotechnology applications in clinical trials**  
BÜYÜKKÖROĞLU G., ŞENEL B., ŞALVA E., ÇALIŞKAN F. B.  
in: Biotechnology in Healthcare, Volume 2: Applications and Initiatives, Debmalya Barh, Editor, Elsevier Academic Press, pp.163-195, 2022
- II. **Characteristics of Marketed Nanopharmaceutics**  
ŞALVA E., TONBUL H.  
in: Drug Delivery with Targeted Nanoparticles: In Vitro and In Vivo Evaluation Methods, Çapan, Y., Sahin, A., Tonbul, H., Editor, Jenny Stanford Publishing, pp.705-720, 2021
- III. **Characteristics of Marketed Nanopharmaceutics**  
ŞALVA E., TONBUL H.  
in: Drug Delivery with Targeted Nanoparticles: In Vitro and In Vivo Evaluation Methods (1st ed.), Yılmaz Çapan, Adem Sahin, Hayrettin Tonbul, Editor, Jenny Stanford Publishing, pp.705-724, 2021
- IV. **Non viral siRNA and shRNA delivery systems in cancer therapy**  
ŞALVA E., EKENTOK C., OZBAS-TURAN S., AKBUGA F. J.  
in: RNA Interference, Ibrokhim Y. Abdurakmonov, Editor, Intech, Rijeka, pp.201-222, 2016
- V. **Hücre ve Moleküler Biyoloji Sözlüğü**  
GÜLSOY N., ALTINKUT UNCUOĞLU A., AYDIN Y., HASDEMİR M. U., AKBUGA F. J., ŞALVA E.  
Nobel Tıp Kitapevi Yayınları, İstanbul, 2014
- VI. **Physical and transfectional properties of aged pIL-2 loaded chitosan microspheres**  
OZBAS TURAN S., ŞALVA E., AKBUGA J.  
in: Advances in Chitin Science Vol XIII, Varlamov V., Bratskaya S., Yakovleva I., Senel S., Editor, Euchis, Saint Petersburg, pp.100-50, 2011
- VII. **Chitosan of nanoparticles containing siRNA targeting VEGF for anti-angiogenic gene therapy**  
ŞALVA E., OZBAS TURAN S., AKBUGA F. J.  
in: Advances in Chitin Science Vol XIII, Varlamov V., Bratskaya S., Yakovleva I., Senel S., Editor, Euchis, Saint Petersburg, pp.201-222, 2011
- VIII. **Sağlık Hizmetleri Meslek Yüksekokulu Eğitimcilerinde Olması Beklenen Özellikler**  
ÇAKALAĞAOĞLU F., ÖZKAN N., ŞALVA E.  
in: Geçmişten Geleceğe Sağlık Teknikerliği, GÖZİL R., Editor, Gazi Üniversitesi, Ankara, pp.100-120, 2008

## Refereed Congress / Symposium Publications in Proceedings

- I. **Silica Nanoparticles as Drug and siRNA Delivery System**  
ULTAV G., TONBUL H., ŞALVA E.  
3rd International Conference on Materials Science and Nanotechnology, Roma, Italy, 3 - 07 October 2022
- II. **Kızılıncık Meyvelerinin Ham, Yarı-Olgun Ve Olgun Dönemlerindeki Biyokimyasal Değişimlerinin İncelenmesi**  
UĞUR Y., Yaman R., Ernim C., Günhan Z. İ., ŞALVA E., ERDOĞAN S.

10. Ulusal Analitik Kimya Kongresi, Muğla, Turkey, 7 - 11 September 2022, pp.94
- III. **"Kızılçık Meyvelerindeki Fenolik Bileşiklerin Olgunlaşma Periyodundaki Değişimi Ve Sitotoksik Etkilerinin Araştırılması"**  
Uğur Y., Yaman R., Ernim C., Günhan Z. İ., Şalva E., Erdoğan S.  
Analitik Kimya Kongresi, Muğla, Turkey, 7 - 11 November 2022, pp.92-93
- IV. **Combination Therapy Approach of Doxorubicin and siRNA with Biodegradable Silica Nanoparticles**  
ULTAV G., TONBUL H., ŞALVA E.  
The 4th International Conference on Graphene and Novel Nanomaterials (GNN 2022), Shenzhen, China, 8 - 11 August 2022
- V. **DETERMINATION OF EFFECTIVE SURFACE MODIFICATIONS OF SILICA NANOPARTICLES AS VEGF-TARGETED siRNA CARRIERS**  
ULTAV G., TONBUL H., ŞALVA E.  
13th International Symposium on Pharmaceutical Sciences (ISOPS), Turkey, 22 June 2021
- VI. **Actively targeted chitosan-based vector for efficient CRISPR-Cas9 mediated Tenascin-C gene editing in triple negative breast cancer**  
Şalva E.  
European Society Gene and Cell Therapy, Hannover, Germany, 19 - 21 October 2021, pp.105
- VII. **The cellular uptake and endosomal escape mechanisms of chitosan-protamine-siRNA nanoplexes for efficient gene transfection and silencing**  
Şalva E.  
BioTürkiye International Biotechnology Congress, İstanbul, Turkey, 9 - 11 September 2021, pp.156
- VIII. **EVALUATION AND CHARACTERIZATION OF FOLIC ACID MODIFIED SILICA NANOPARTICLES AS SIRNA CARRIERS**  
ULTAV G., ŞALVA E., TONBUL H.  
3rd International Gazi Pharma Symposium Series (GPSS- 2021), Turkey, 08 September 2021
- IX. **GESTASYONEL DİABETES MELLİTUSTA GUANOZİN TRİFOSFAT SİKLOHİDROLAZ İVE ENDOTELYAL NİTRİK OKSİT SENTAZ GEN EKSPRESYONLARININDEĞERLENDİRİLMESİ**  
YÜCE H., ŞALVA E., ACAR C., MELEKOĞLU R., ÜNÜVAR S.  
1. ULUSLARARASI MALATYA UYGULAMALI BİLİMLER KONGRESİ, 20 - 22 December 2019
- X. **EVALUATION OF GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I AND ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE EXPRESSIONS IN GESTATIONAL DIABETES MELLITUS**  
YÜCE H., ŞALVA E., ACAR C., MELEKOĞLU R., ÜNÜVAR S.  
1. ULUSLARARASI MALATYA UYGULAMALI BİLİMLER KONGRESİ, Malatya, Turkey, 20 - 22 December 2019, vol.1, pp.326-327
- XI. **IN VITRO ANTICANCER ACTIVITY OF NEW NAPHTHYL ETHANONE OXIME ESTER DERIVATIVES BEARING PYRAZOLE MOIETY**  
BOZBEY İ., USLU H., ŞALVA E., KARAKURT A.  
12th International Symposium on Pharmaceutical Sciences, ISOPS-12, Ankara, Turkey, 26 - 29 June 2018, pp.380
- XII. **The investigation of effects to cell proliferation and adsorption of new ternary and binary scaffolds**  
Sirkeci A., ŞALVA E., TURAN S., Akbuga J.  
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, Italy, 18 - 21 October 2016, vol.27
- XIII. **Comparison of short and long siVEGF/encapsulating chitosan nanoparticles in breast cancer cell lines**  
CÖMEZ B., Akbuga J., ŞALVA E.  
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, Italy, 18 - 21 October 2016, vol.27
- XIV. **Tumor Inhibition by Using Chitosan: siRNA PDGFR-beta in Breast Cancer Model of Rat**  
Akbuga J., Turan S. O., ŞALVA E., Ozkan N., KABASAKAL L., Alan S.  
19th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, Kiribati, 4 - 07 May 2016, vol.24



- XV. **Lapatinib sinovyal fibroblastlardan matriksmetalloproteinazların salınımını baskılar**  
ÖZGEN M., emmungil h., ŞALVA E., BAŞAK N., ÇİFTÇİ O.  
XVI. ULUSAL ROMATOLOJİ KONGRESİ, Turkey, 29 October - 01 November 2015
- XVI. **The effect of tumor suppressive miR-200c and miR-141 optimization in breast cancer cell lines.**  
KABAN K., ŞALVA E., AKBUGA J.  
11th Annual Meeting of the Oligonucleotide Therapeutics Society, Leiden, Netherlands, 11 - 14 September 2015, pp.59
- XVII. **PDGF-D Inhibition by Using Chitosan: siRNA Complexes in Breast Cancer Model of Rat**  
Akbuga J., Ozbas-Turan S., KABASAKAL L., Salva E., Ozkan N.  
18th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Louisiana, United States Of America, 13 - 16 May 2015, vol.23
- XVIII. **Co-Delivery of VEGF siRNA and IL-4 into Chitosan Nanoparticles in Breast Tumor Model of Rat**  
ŞALVA E., Ozbas-Turan S., KABASAKAL L., EREN F., Alan S., Ozkan N., Akbuga J.  
16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Utah, United States Of America, 15 - 18 May 2013, vol.21
- XIX. **Protamine Containing Chitosan:shRNA Complexes for Silencing of VEGF Expression**  
Cakmak F. E., Turan S. O., Salva E., Akbuga J.  
15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Pennsylvania, United States Of America, 16 - 19 May 2012, vol.20
- XX. **Chitosan Mediated VEGF shRNA Transfer for the Treatment of Breast Cancer**  
Salva E., KABASAKAL L., Ozkan N., EREN F., ÇAKALAGA OĞLU F., Akbuga J.  
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010, vol.21, pp.1411
- XXI. **Chitosan nanoparticles containing shRNA targeting VEGF as cancer therapeutic**  
Salva E., OZBAS-TURAN S., Akbuga J.  
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010, vol.21, pp.1412-1413
- XXII. **Intramuscular Delivery of Antisense Oligonucleotides by Chitosan Nanoparticles**  
Ozbas-Turan S., Akbuga J., SEZER A., Salva E.  
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010, vol.21, pp.1452-1453
- XXIII. **Characterization and in vitro silencing effect of chitosan/siRNA complexes**  
Salva E., Akbuga J.  
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1158
- XXIV. **Expression of MMP2, HPV and ALPHA-1 antichymotrypsin as prognostic markers for squamous cell carcinoma of the larynx**  
ÇAKALAGA OĞLU F., TUZUNER B., OZKAN N., Salva E., Gergin O., Sari M., KAYA H.  
27th International Congress of the International-Academy-of-Pathology, Athens, Greece, 12 - 17 October 2008, vol.53, pp.211
- XXV. **Development of a novel delivery system for antisense oligonucleotides**  
ENNELI B., Salva E., AKBUGA J.  
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.132
- XXVI. **Delivery of GM-CSF gene using chitosan complexes**  
Salva E., ENNELI B., AKBUGA J.  
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.132

## Supported Projects

- ÖZTÜRK N., ŞALVA E., ALAN S., TONBUL H., Project Supported by Higher Education Institutions, Dosetaksel içeren çok fonksiyonlu hibrit nanopartiküllerin hazırlanması ve in vitro değerlendirilmesi, 2022 - Continues
- ŞALVA E., TUBITAK Project, Meme kanser hücreleri ve meme kanser kök hücrelerinde gen tedavisi: VEGF'in kitozan/CRISPR-Cas9/protamin nanopleksleri ile baskılanması, 2018 - Continues
- ŞALVA E., TUBITAK Project, Bcl-2 hedefli siRNA yüklü NK-kaynaklı eksozomların oluşturulması ve meme kanserinde etkinliğinin araştırılması, 2018 - Continues
- Ultav G., Öztürk S. C., Esendağlı G., Alan S., Akbuğa F. J., Şalva E., TUBITAK Project, Doksorubisin Yüklü Hedeflendirilmiş NK Kaynaklı Eksozomların Ewing Sarkomu Tedavisinde Etkinliğinin İncelenmesi, 2024 - 2026
- ŞALVA E., ARISOY S., TONBUL H., ÖZTÜRK N., ATEŞ M., ULTAV G., Project Supported by Higher Education Institutions, Meme Kanseri Tedavisinde İlaç Direncine Karşı Yenilikçi Nanoterapötik Yaklaşımların Geliştirilmesi, 2020 - 2024
- Tonbul H., Şalva E., Ultav G., TUBITAK Project, Redoks Yanıtı Silika Nanopartiküller ile İlaç ve Gen Taşıyıcı Sistem Hazırlanması ve In Vitro Değerlendirmesi, 2021 - 2023
- TONBUL H., ULTAV G., ŞALVA E., Project Supported by Higher Education Institutions, GM-CSF İçeren Silika Nanopartiküllerinin İnflamazom Aracılı Adjuvan Etkisinin Araştırılması, 2021 - 2022
- ŞALVA E., ÖZBAŞ TURAN S., BAREKE H., ALAN S., SÖZER KARADAĞLI S., Project Supported by Higher Education Institutions, Meme Tümörü ve Mikroçevresinde Ekspresye Olan Tenascin-C'nin Genom Düzenlemesi ile Kanserde Yeni Bir Terapötik Yaklaşımın Geliştirilmesi, 2019 - 2022
- ŞALVA E., ÖZBAŞ TURAN S., ÇÖMEZ B., EKENTOK ATICI C., Project Supported by Higher Education Institutions, siRNA ve shRNALARIN Farklı Polimerler ile Hazırlanan Nanoplekslerinin İn Vitro Gen Susturma, Hücreyel Alım ve Endozomal Kaçış Etkinliklerinin Karşılaştırılması, 2019 - 2021
- ŞALVA E., KABAN K., Project Supported by Higher Education Institutions, Lentiviral vektörle NK hücre manipülasyonu ve eksozomlarının meme kanserinde etkinliği, 2017 - 2020
- ÜNÜVAR S., ACAR C., ŞALVA E., MELEKOĞLU R., Project Supported by Higher Education Institutions, Guanozin Trifosfat Yolağında Tetrahidrobiyopterin Bağımlı Nitrik Oksit Düzeylerindeki Değişikliklerin Gestasyonel Diabetes Mellitusta Değerlendirilmesi, 2018 - 2019
- YILMAZ İ., ALAN S., ŞALVA E., TUBITAK Project, Glomerulonefrit tedavisinde siRNA taşıyıcı sistem olarak kitozan nanoplekslerinin kullanılması, 2013 - 2016
- ŞALVA E., TUBITAK Project, shVEGF içeren kitozan nanoplekslerinin meme kanser hücre hatlarında hücre invazyonu proliferasyonu ve koloni oluşturma üzerine etkilerinin araştırılması, 2015 - 2015
- ŞALVA E., Project Supported by Other Private Institutions, Kanseri tedavisinde siRNA uygulamaları için taşıyıcı sistem geliştirilmesi, 2007 - 2009
- ŞALVA E., TUBITAK Project, GM CSF kodlayan gen taşıyıcı sistemler, 2007 - 2008

## Memberships / Tasks in Scientific Organizations

- Farmasötik Biyoteknoloji Derneği, Board Member, 2014 - Continues
- ESGCT, Member, 2008 - Continues

## Metrics

- Publication: 72
- Citation (WoS): 362
- Citation (Scopus): 420
- H-Index (WoS): 12
- H-Index (Scopus): 13

## Awards

Şalva E., The cellular uptake and endosomal escape mechanisms of chitosan-protamine-siRNA nanoplexes for efficient gene transfection and silencing, Biotürkiye Uluslararası Biyoteknoloji Kongresi, September 2021

ŞALVA E., TUBİTAK Yayın Teşvik Ödülü, Tübitak, June 2012

Şalva E., En iyi poster ödülü, Perspectives İn Cell And Gene Based Medicines, March 2012

ŞALVA E., TUBİTAK Yayın Teşvik Ödülü, Tübitak, June 2011

ŞALVA E., Novartis Farmasötik Teknoloji Proje Destek Ödülü, Novartis, April 2011

ŞALVA E., Marmara Üniversitesi Yayın Teşvik Ödülü, Marmara Üniversitesi, December 2010

ŞALVA E., TUBİTAK Yayın Teşvik Ödülü, Tübitak, June 2010

ŞALVA E., Bildiri Birincilik Ödülü, Akademik Geriatri Kongresi, May 2010

ŞALVA E., Terry Fox Kanser Araştırma Proje Grant, Terry Fox, March 2007